A new research review published in the Journal of Neurology urges clinicians and researchers to look beyond muscle weakness when evaluating and treating myasthenia gravis (MG). While MG is widely recognized for its hallmark motor symptoms, such as drooping eyelids, difficulty swallowing and muscle fatigue, researchers suggest that the disease’s impact may be far broader than previously understood.
The review details emerging evidence showing that MG may also affect cognitive function, mood, sleep and multiple organ systems. These symptoms, which have historically received little attention, could significantly influence patient well-being and disease outcomes.
Researchers note a range of nonmotor symptoms including anxiety, depression, memory problems, autonomic dysfunction, gastrointestinal disturbances, cardiovascular abnormalities and sensory complaints that can affect people living with MG. Sleep disorders, such as sleep apnea and insomnia, may also be more common among those with the condition.
Learn more about MG prognosis
Several biological mechanisms may explain these symptoms, including immune dysregulation, autonomic imbalance and potential antibody cross-reactivity, noted the study’s authors. They explained that the same immune system dysfunction that targets acetylcholine receptors at the neuromuscular junction may also affect similar receptor types found in other parts of the body, including the brain and autonomic nervous system. This could contribute to problems regulating heart rate, digestion, sleep and emotional responses.
While many patients and clinicians have reported symptoms beyond muscle weakness, these experiences have historically been overlooked or attributed to medication side effects, fatigue or stress. The review argues that recognizing them as potential features of MG could help improve quality of life and treatment outcomes.
The review calls for larger, prospective studies to better understand how common these symptoms are, what mechanisms cause them and how they can be effectively treated.
“Ultimately, a more integrated view of MG — encompassing both motor and non-motor dimensions — may improve patient care, early diagnosis, and individualized treatment strategies, thereby addressing the full clinical spectrum of this complex autoimmune disease,” the study’s authors concluded.
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
